Abstract
Perflenapent emulsion (EchoGen®, SONUS Pharmaceuticals, Bothell, Wash.) is a phase‐shift colloid that is the first of a new class of intravenously injectable fluorocarbon‐based ultrasound contrast agents, representing a significant advance in contrast echocardiography. Unlike currently available contrast agents, perflenapent emulsion effectively opacifies the left ventricle and enhances endocardial border delineation. The persistence of the contrast effect permits interrogation in multiple echocardiographic views. Perflenapent emulsion should permit the use of echocardiography to visualize and localize myocardial perfusion deficits at rest by producing a negative contrast effect, allowing physicians to diagnose coronary artery disease, including the extent of a lesion's impact on the perfusion of the myocardium, in a timely and cost‐efficient manner. Perflenapent emulsion is also easy to use and requires no preparation, reconstitution, or refrigeration.
Keywords: perflenapent emulsion, EchoGen®, phase‐shift colloid, contrast echocardiography, fluorocarbon
Full Text
The Full Text of this article is available as a PDF (1.9 MB).
References
- 1. Correas J‐M, Quay SC: EchoGen® emulsion: A new ultrasound contrast agent based on phase shift colloids. Clin Radiol 1996; 51 (suppl I): II–14 [PubMed] [Google Scholar]
- 2. Correas J‐M, Kessler D, Worah D, Quay SC: The first phase shift ultrasound contrast agent: EchoGen® In Ultrasound Contrast Agents (Ed. Goldberg BB.), p.101–120. London, Martin Dunitz, 1997. [Google Scholar]
- 3. Grayburn PA, Hack TC, Weiss JL, Raichlen JS, Vannan MA, Klein AL, Kitzman DW, Chrysant SG, Cohen JL, Abrahamson D, Foster E, Perez JE, Aurigemma GP, Panza JA, Picard MH, Byrd BF III, Segar DS, Jacobson SA: A phase III trial comparing dodecafluoropentane (EchoGen®) and sonicated albumin (Albunex®) in patients with suboptimal echoes. Presented at the Annual Meeting of the American Heart Association, November 10–13, 1996, New Orleans, La.
- 4. Worah DM, Kessler DR, Menter AR, Huang MG, Correas J‐M, Quay SC: EchoGen® emulsion: Ultrasound contrast media. Drugs of the Future 1997; 22 (4): 378–385 [Google Scholar]
- 5. Melany ML, Grant EG: Clinical experience with sonographic contrast agents. Semin Ultrasound CT MR 1997; 18 (1): 3–12 [DOI] [PubMed] [Google Scholar]
- 6. Crouse LJ, Cheirif J, Hanly DE, Kisslo JA, Labovitz AJ, Raichlen JS, Schutz RW, Shah PM, Smith MD: Opacification and border delineation improvement in patients with suboptimal endocardial border definition in routine echocardiography: Results of the Phase III Albunex Multicenter Trial. J Am Coll Cardiol 1993; 22: 1494–1500 [DOI] [PubMed] [Google Scholar]
- 7. Hundley WG, Kizilbash AM, Afridi I, Franco F, Peshock RM, Grayburn PA: Intravenous dodecafluoropentene improves determination of left ventricular functionduring echocardiography (abstr). J Am Coll Card 1997; 27: 520A [Google Scholar]
- 8. Quay SC, Eisenfeld A: Safety assessment of the use of perflenapent emulsion for the contrast enhancement of echocardiography and diagnostic radiology ultrasound studies. Clin Cardiol October 1997; 20 (suppl 1): [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Albunex® product information. St. Louis, Mo.: Mallinckrodt Medical, 1995. [Google Scholar]
- 10. Grayburn PA, Erikson JM, Escobar J, Womack L, Velasco CE: Peripheral intravenous myocardial contrast echocardiography using a 2% dodecafluorepentane emulsion: Identification of myocardial risk area and infarct size in the canine model of ischemia. J Am Coll Cardiol 1995; 26: 1340–1347 [DOI] [PubMed] [Google Scholar]
- 11. Feigenbaum H: Echocardiography. 5th ed, p. 68–133. Philadelphia, Pa: Lea & Febiger, 1994. [Google Scholar]
- 12. Yvorchuk KJ, Sochowski RA, Chan KL: Sonicated albumin in exercise echocardiography: Technique and feasibility to enhance endocardial visualization. J Am Soc Echocardiogr 1996; 9 (4): 462–469 [DOI] [PubMed] [Google Scholar]